MRNA.O
Latest Trade
157.43USDChange
5.50(+3.62%)Volume
19,123,403Today's Range
-
164.5552 Week Range
-
178.50As of on the NASDAQ ∙ Minimum 15 minute delay
Jan 25 (Reuters) - Moderna Inc <MRNA.O>::Moderna CMO says currently looking at studying a third COVID-19 booster shot 6 to 12 months after second vaccine shot, but not sooner- conf. call.Moderna exec says expect the durability of protection from the primary series of its COVID-19 vaccine to be a year or longer- conf.call.Further company coverage: MRNA.O. (Reporting By Michael Erman). ((Michael.Erman@thomsonreuters.com;)).
Jan 11 (Reuters) - Moderna Inc <MRNA.O>::CEO SAYS EXPECTS 2021 POTENTIAL REVENUES OF $11.7 BILLION IF PRODUCTS ARE DELIVERED IN THIS YEAR- JPM CONF. CALL.CEO SAYS EXPECTS TO DELIVER 600 MILLION DOSES OF ITS COVID-19 VACCINE IN 2021- JPM CONF. CALL.CEO SAYS IS VERY COMFORTABLE TO ACHIEVE UP TO 1 BILLION DOSES OF ITS COVID-19 VACCINE IN 2021- JPM CONF. CALL.EXECUTIVE SAYS MODERNA'S TECHNOLOGY IS VERY WELL SUITED TO RAPIDLY DEPLOY A VACCINE BASED ON THE NEW VARIANT- JPM CONF. CALL.SAYS BASED ON AVAILABLE EVIDENCE TO DATE, VACCINE IMMUNITY SHOULD LAST AT LEAST A YEAR- JPM CONF. CALL.Further company coverage: <MRNA.O>. ((Reuters.Briefs@thomsonreuters.com;)).
Jan 11 (Reuters) - Moderna Inc <MRNA.O>::MODERNA PROVIDES BUSINESS UPDATE AND ANNOUNCES THREE NEW DEVELOPMENT PROGRAMS IN INFECTIOUS DISEASE VACCINES.MODERNA INC - MODERNA NOW HAS ONE COMMERCIAL MEDICINE AND 24 DEVELOPMENT PROGRAMS.MODERNA INC - MULTIPLE THERAPEUTIC PROGRAMS ANTICIPATED TO SEE CLINICAL PROOF OF CONCEPT DATA IN 2021.MODERNA INC - HIV VACCINE PROGRAM TO ACCELERATE HUMAN VALIDATION OF NOVEL VACCINATION STRATEGIES.MODERNA INC - ALSO ANNOUNCED AN EXPANSION OF ITS RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE PROGRAM INTO OLDER ADULTS.MODERNA INC - NIPAH VACCINE PROGRAM ESTABLISHED AGAINST A VIRUS OF PUBLIC HEALTH CONCERN.MODERNA INC - EXPECTS TO BEGIN PHASE 1 CLINICAL TRIALS FOR BOTH MRNA-1644 AND MRNA-1574 IN 2021.MODERNA INC - TO DATE, PRODUCT REVENUE ASSOCIATED WITH APAS FOR DELIVERY OF ITS COVID-19 VACCINE FOR FY 2021 IS $11.7 BILLION.MODERNA INC - IS IN ACTIVE DISCUSSIONS TO SIGN ADDITIONAL APAS FOR DELIVERIES IN 2021 AND 2022.MODERNA INC - ALSO MADE A PROPOSAL TO COVAX VIA A UNICEF TENDER TO SUPPLY LOW-AND-MID INCOME COUNTRIES.
Jan 8 (Reuters) - :U.K. IS REVIEWING MODERNA'S COVID-19 VACCINE ON AN ACCELERATED TIMETABLE, POISED TO AUTHORIZE IT FOR EMERGENCY USE AS SOON AS FRIDAY - BLOOMBERG.
Jan 6 (Reuters) - Moderna Inc <MRNA.O>::EUROPEAN COMMISSION AUTHORIZES COVID-19 VACCINE MODERNA IN EUROPE.MODERNA INC - EUROPEAN COMMISSION HAS SECURED 160 MILLION DOSES; FIRST DELIVERIES TO COUNTRIES WILL BEGIN NEXT WEEK.MODERNA INC - ADDITIONAL AUTHORIZATIONS ARE CURRENTLY UNDER REVIEW IN SINGAPORE, SWITZERLAND AND UNITED KINGDOM..
Jan 6 (Reuters) - European Medicines Agency::EMA RECOMMENDS COVID-19 VACCINE MODERNA FOR AUTHORISATION IN EU.EMA SAYS COVID-19 VACCINE MODERNA IS GIVEN AS TWO INJECTIONS INTO ARM, 28 DAYS APART.EMA SAYS RECOMMENDED GRANTING CONDITIONAL MARKETING AUTHORISATION FOR COVID-19 VACCINE MODERNA IN PEOPLE FROM 18 YEARS OF AGE..EMA SAYS THE EUROPEAN COMMISSION WILL NOW FAST-TRACK DECISION-MAKING PROCESS TO GRANT A DECISION ON THE CONDITIONAL MARKETING AUTHORISATION FOR COVID-19 VACCINE MODERNA.EMA SAYS COMPANY THAT MARKETS COVID-19 VACCINE MODERNA WILL CONTINUE TO PROVIDE RESULTS FROM THE MAIN TRIAL, WHICH IS ONGOING, FOR 2 YEARS.
Jan 5 (Reuters) - :SCIENTISTS ARE STUDYING IF THE MODERNA VACCINE SUPPLY CAN BE DOUBLED BY CUTTING DOSES IN HALF - NYT.
Jan 4 (Reuters) - :FDA STATEMENT ON FOLLOWING THE AUTHORIZED DOSING SCHEDULES FOR COVID-19 VACCINES.FDA SAYS "TWO DIFFERENT MRNA VACCINES HAVE NOW SHOWN REMARKABLE EFFECTIVENESS OF ABOUT 95% IN PREVENTING COVID-19 INFECTION IN ADULTS".FDA - "SUGGESTING CHANGES TO THE FDA-AUTHORIZED DOSING OR SCHEDULES OF THESE VACCINES IS PREMATURE AND NOT ROOTED SOLIDLY IN THE AVAILABLE EVIDENCE".FDA - AVAILABLE DATA CONTINUE TO SUPPORT THE USE OF TWO SPECIFIED DOSES OF EACH AUTHORIZED VACCINE AT SPECIFIED INTERVALS.FDA-FOR PFIZER-BIONTECH VACCINE, INTERVAL IS 21 DAYS BETWEEN 1ST & 2ND DOSE; FOR MODERNA COVID-19 VACCINE, INTERVAL IS 28 DAYS BETWEEN 1ST & 2ND DOSE.FDA- "WHAT WE HAVE SEEN IS THAT THE DATA IN THE FIRMS’ SUBMISSIONS REGARDING THE FIRST DOSE IS COMMONLY BEING MISINTERPRETED".FDA- UNTIL VACCINE MAKERS HAVE DATA SUPPORTING CHANGE, WE CONTINUE TO STRONGLY RECOMMEND HEALTH CARE PROVIDERS FOLLOW FDA-AUTHORIZED DOSING SCHEDULE.
Jan 4 (Reuters) - Moderna Inc <MRNA.O>::MODERNA PROVIDES COVID-19 VACCINE SUPPLY UPDATE.MODERNA INC - CONTINUES TO INVEST AND HIRE IN ORDER TO DELIVER UP TO 1 BILLION DOSES IN 2021.MODERNA INC - RAISES LOWER END OF GLOBAL MANUFACTURING PLAN FOR 2021 FROM 500 MILLION DOSES PREVIOUSLY TO 600 MILLION DOSES.MODERNA INC - CONTINUES TO INVEST AND HIRE IN ORDER TO DELIVER UP TO 1 BILLION DOSES IN 2021.MODERNA INC - EXPECTS ABOUT 100 MILLION DOSES TO BE AVAILABLE IN UNITED STATES BY END OF Q1 OF 2021.MODERNA INC - REPORTED THAT APPROXIMATELY 18 MILLION DOSES HAVE BEEN SUPPLIED TO U.S. GOVERNMENT TO DATE.MODERNA - ADDITIONAL VACCINE DOSES HAVE BEEN SUPPLIED TO CANADIAN GOVERNMENT FOLLOWING AUTHORIZATION BY HEALTH CANADA'S INTERIM ORDER ON DEC 23, 2020.MODERNA INC - EXPECTS ABOUT 100 MILLION DOSES TO BE AVAILABLE IN UNITED STATES BY END OF Q1 OF 2021, WITH 200 MILLION DOSES TOTAL AVAILABLE BY END OF Q2.
Dec 23 (Reuters) - Moderna Inc <MRNA.O>::MODERNA INC - STATEMENT ON VARIANTS OF SARS-COV-2 VIRUS.MODERNA -RANGE OF POTENTIAL NEUTRALIZING ANTIBODIES PROVIDE CONFIDENCE COVID-19 VACCINE WILL BE EFFECTIVE AT INDUCING NEUTRALIZING ANTIBODIES AGAINST ANY STRAIN.MODERNA - TESTED SERA FROM ANIMALS, HUMANS VACCINATED WITH CO'S COVID-19 VACCINE AGAINST NUMBER OF PRIOR VARIANTS OF VIRUS THAT EMERGED SINCE OUTBREAK.MODERNA - EXPECTS VACCINE-INDUCED IMMUNITY CO'S COVID-19 VACCINE WOULD BE PROTECTIVE AGAINST VARIANTS OF SARS-COV-2 VIRUS RECENTLY DESCRIBED IN THE UK.MODERNA - WILL BE PERFORMING ADDITIONAL TESTS OF CO'S COVID-19 VACCINE IN COMING WEEKS TO CONFIRM EXPECTATION AGAINST VARIANTS OF VIRUS DESCRIBED IN UK.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.